Author Archives: Kelly Pisarev Lord

25 Years of Biologics Development and Manufacturing Experience

by

Avid Bioservices is a full-service, dedicated contract development and manufacturing organization (CDMO) focused on development and manufacturing of biopharmaceutical products derived from mammalian cell culture. Avid provides process development and CGMP clinical and commercial product manufacturing and offers expertise supporting analytical development, qualification, and validation activities. Additional service offerings include cell line optimization, cell culture and feed optimization, product characterization, and stability testing. Avid has 25 years of experience producing a comprehensive range of proteins, including monoclonal antibodies and recombinant…

August 24, 2018

Continued Expansion of Our State-of-the-Art Facilities and Services: Meeting All Your Manufacturing Needs from Development to Commercialization

by

Avid Bioservices is a contract development and manufacturing organization (CDMO) specializing in mammalian cell culture process development and cGMP production of clinical and commercial-scale monoclonal antibodies, recombinant proteins, and enzymes. Committed to the success of our clients, our team constantly strives to build partnerships that extend well beyond the delivery of your product. By combining our knowledge and experience with a flexible and efficient approach, we can meet your specific project requirements. Established CDMO with a Broad Range of Capabilities…

August 10, 2017

Your Partner from Concept to Commercial

by

Avid Bioservices is a contract manufacturing organization (CMO) specializing in mammalian cell culture process development and current good manufacturing practice (CGMP) production of clinical- and commercial-scale monoclonal antibodies, recombinant proteins, and enzymes. Committed to your success, our team is constantly striving to build partnerships that extend well beyond the delivery of product. By combining our knowledge and experience with a flexible and efficient approach, we can meet your specific project requirements. Established CMO with Proven Capabilities nearly two decades of…

August 15, 2014

Avid Bioservices

by

Avid Bioservices is your CMO partner offering a suite of fully integrated, comprehensive biomanufacturing services that support the development and cGMP production of clinical and commercial-stage monoclonal antibodies, recombinant proteins, and enzymes. Our client’s success is our main focus. With over 15 years of experience, Avid provides services that support every phase of development: cell line optimization, process development, analytical methods development, clinical and commercial cGMP manufacturing, and regulatory support. As the wholly owned subsidiary of Peregrine Pharmaceuticals, a clinical-stage…

August 1, 2013

Capacity to Accelerate Success

by

As a CMO partner, Avid Bioservices provides fully integrated services across the process chain to develop and commercialize a biologic including cell line and process development, analytical methods development, clinical and commercial cGMP manufacturing, and regulatory submissions. We provide first-hand expertise and knowledge to navigate a biologic from concept to commercialization because we are a wholly owned subsidiary of Peregrine Pharmaceuticals, a clinical-stage, publicly traded biotech company with a management team experienced in the development and commercialization of therapeutic proteins.…

August 1, 2011

Avid Bioservices

by

Avid Bioservices offers a fresh approach to the Contract Manufacturing organization (CMO)–client relationship: fully integrated services across the process chain, including cell line and process development, analytical methods development, cGMP manufacturing, fill/finish, regulatory submission, and commercialization of biologic drug product or drug substance. our expertise enables our clients to succeed in their ventures. As a wholly owned subsidiary of Peregrine Pharmaceuticals, a clinical-stage biotech company with a management team experienced in the commercialization of therapeutic proteins, we know what it…

July 1, 2010